Trial Profile
Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion Without Water
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ramosetron (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacokinetics
- 15 Jul 2011 New trial record